Semaglutide cut fentanyl seeking in rats

A preclinical study published in Behavioural Pharmacology on 2 June 2026 found that acute doses of semaglutide blocked fentanyl-seeking behaviour in male rats across all three standard relapse triggers: cues, a priming dose of fentanyl itself, and pharmacological stress^[1]. The findings add to a growing body of animal research suggesting that GLP-1 receptor agonists may influence the brain's reward circuitry in ways relevant to opioid use disorder (OUD).

What the study tested

Researchers at Penn State College of Medicine trained male Sprague-Dawley rats to self-administer intravenous fentanyl, then tested whether a single subcutaneous injection of semaglutide at three dose levels (0.026, 0.056 and 0.078 mg/kg) could reduce reinstatement of fentanyl seeking^[1]. Reinstatement is the standard laboratory model for relapse: the animal has learned to press a lever for the drug, the drug is withdrawn, and then a trigger is introduced to see whether the animal returns to lever-pressing.

Three triggers were tested separately. Drug-induced reinstatement used a priming injection of 1.85 micrograms per kilogram of intravenous fentanyl. Stress-induced reinstatement used 0.5 mg/kg of yohimbine, a compound that reliably produces a stress response in rodents. Cue-induced reinstatement used the light and tone signals the rats had learned to associate with drug delivery^[1].

What the results showed

All three semaglutide doses completely prevented drug-induced and stress-induced fentanyl seeking. For cue-induced seeking, the mid-dose (0.056 mg/kg) and highest dose (0.078 mg/kg) were most effective at reducing lever-pressing^[1]. The lowest dose (0.026 mg/kg) showed a partial effect on cue-induced reinstatement but still fully blocked the other two triggers.

The authors noted that semaglutide's long half-life (roughly one week in humans) could make it practical as a weekly injection in clinical settings. That distinguishes it from shorter-acting GLP-1 receptor agonists such as exendin-4 that have been tested in earlier preclinical addiction research but require more frequent dosing. A once-weekly injection would fit more easily into the existing clinical infrastructure for OUD treatment, where patients already attend regular appointments for buprenorphine or methadone.

Why GLP-1 receptors matter for addiction research

GLP-1 receptors are found not only in the pancreas and gut but also in brain regions involved in reward processing, including the nucleus accumbens and the ventral tegmental area. These are the same circuits that drive compulsive drug seeking. A 2026 systematic review covering 41 studies (35 preclinical, 6 clinical) found that GLP-1 receptor agonists reduced substance intake and relapse-like behaviours across multiple drug classes, including alcohol, nicotine, cocaine and opioids^[2]. The mechanism appears to involve dampening of dopamine-driven reward signalling, though the precise pathways are still being mapped.

The broader interest in GLP-1 receptor agonists for addiction is partly epidemiological. Large observational studies using insurance-claims data have reported lower rates of alcohol and opioid use diagnoses among patients prescribed semaglutide or liraglutide for diabetes or obesity. Those findings are suggestive but cannot prove causation, which is why controlled trials in both animals and humans are needed^[2].

The same Penn State group behind the current rat study has registered a Phase II randomised controlled trial (NCT06548490) to test semaglutide in 200 adults receiving buprenorphine or methadone maintenance for OUD^[3]. That trial will measure opioid abstinence over 19 weeks. Until human data arrive, the clinical relevance of the rat findings remains speculative.

What this does not tell us

Rat reinstatement models capture one dimension of relapse, but human addiction involves social, psychological and environmental factors that no animal model reproduces fully. The study used only male rats, so sex-dependent differences are unknown. Previous research on other GLP-1 receptor agonists has sometimes found different effect sizes in female animals, making this a gap worth flagging.

The doses were acute (single injection), not chronic, so tolerance, side-effect burden over time and interaction with existing OUD medications were not assessed. The fentanyl self-administration paradigm, while standard, does not replicate the chaotic dosing patterns of illicit fentanyl use in humans. And the gastrointestinal side effects that are common with semaglutide in clinical use (nausea, vomiting, appetite suppression) could confound behavioural measures in ways that are difficult to separate from a genuine anti-relapse effect.

Semaglutide is currently approved for type-2 diabetes and chronic weight management, not for substance use disorders. Any off-label use for addiction would require clinical evidence that does not yet exist. If you or someone you know is dealing with opioid use disorder, speak with a healthcare professional about evidence-based treatments that are already approved.